Am J Manag Care.
There were 2 errors in the supplement, "Fracture Prevention in Osteoporosis." First, in Figure 1 on page S192 of the article "Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-world Setting," by Diana Brixner, PhD, RPh,(2006;12[suppl 7]:S191-S198), the bars representing the VERTNA [Vertebral Efficacy With Risedronate Therapy-North America] study were inadvertently switched with the placebo bars. Second, in the same figure, the acronym VERT-MIN was incorrect; the correct acronym is VERT-MN [Vertebral Efficacy With Risedronate Therapy-Multinational]. The corrected figure appears below.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More